Overview

OraSure (OSUR) is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. 

Its innovative products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. In addition, the Company is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications. 

OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, and commercial and industrial entities. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.

OSUR Investor Highlights

• Announced that the U.S. Food and Drug Administration (FDA) Blood Products Advisory Committee provided a unanimous positive recommendation for the Company's OraQuick^(R) In-Home HIV Test.

• Consolidated revenues were $20.9 million for the first quarter of 2012, a 20% increase from the comparable quarter of 2011.

• Cash totaled $22.8 million at March 31, 2012.

• According to the Centers for Disease Control and Prevention, despite current testing options, there are approximately 1.2 million people in the U.S. that have HIV and approximately 240,000 of them are unaware of their status.

• The OraQuick ADVANCE^(R) test is the first and only FDA-approved and CLIA-waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in oral fluid in 20 minutes.